|View printer-friendly version|
|July 21, 2004 5:12 p.m.|
|Teva Announces Approval Of Terbutaline Sulfate Injection|
Jerusalem, Israel, July 21, 2004 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted final approval for the Company's ANDA for Terbutaline Sulfate Injection, 1 mg/mL. Shipment of this product is expected to begin immediately.